| Name | Title | Contact Details |
|---|
ACM Medical Laboratory, Inc., located at 160 Elmgrove Park in Rochester, NY is a full service testing laboratory. One of the largest and fastest growing regional reference laboratories in the United States, ACM Medical Laboratory has over 30 years of
Good Start Genetics is an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability combined with other technologies to deliver best-in-class tests for routine genetic screening. Through its GoodStart Select(TM) offering, the company provides the most comprehensive and clinically actionable set of tests for known and novel mutations that cause inherited diseases. Good Start`s NGS capabilities can be applied to multiple disease areas, including pre-conception carrier screening in the in-vitro fertilization setting.
Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Headquartered in Shanghai since our founding in 2014, our experienced team has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on our extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development. Through these partnerships, Zai Lab has built the strongest late stage oncology portfolio with global first-in-class and/or best-in-class profile, among innovative Chinese biotech companies. We are further supplementing our pipeline with an in-house discovery effort aiming to produce 1-2 global INDs per year. Zai Lab is rapidly expanding into a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing innovative medicines. To that end, we have built our internal R&D center to advance our discovery pipeline, a strong clinical development and operations team, and our own manufacturing facilities in China. We have also established a highly specialized commercial team to support marketing of our innovative products in China. We believe this integrated approach will provide sustainable competitive advantages for Zai Lab. Zai Lab was successfully listed on the Nasdaq Stock Market in September 2017. Since then, Zai Lab significantly expanded with several offices across China and opened its U.S. headquarters in San Francisco in December 2018. As of December 2019, the Company has a global team of approximately 700 employees.
Nuvectra™ is a neuromodulation company committed to helping physicians improve the lives of people with chronic conditions through our medical devices. At Nuvectra, we focus not only on what our devices do, but also on reducing their complexity for clinicians and patients. We are committed to developing products with intelligent innovations and technologies that provide improved outcomes and long-term solutions for our customers. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder and deep brain stimulation (DBS) for the treatment of Parkinson`s Disease. NeuroNexus, a subsidiary owned by Nuvectra, designs, manufactures, and markets leading-edge neural-interface technologies for the neuroscience clinical research market.
Accumen Inc. partners with health systems to deliver excellence in laboratory and comprehensive patient blood management. Accumen brings together diverse industry expertise and innovative thinking to optimize laboratories for improved cost, quality, service and outreach growth.